Shire has sold its MRT platform, which is an mRNA-based therapy platform developed by its subsidiaries, to RaNA Therapeutics, a Cambridge, Massachusetts-based company focused on RNA-targeted medicines.

Under the agreement, Shire receives an equity stake in RaNA and is eligible for future milestones and royalties on products developed with the technology. In addition, Shire’s former MRT employees who focused on the development of this technology since 2008 have joined RaNA to continue to advance the platform with lead programs in cystic fibrosis (CF) and urea cycle disorders (UCD).

Source: RaNA Therapeutics